Dutch court blocks subcutaneous Keytruda in eight European countries

RegulatorynegativeKeytrudaNegative

AI Analysis

Summary

A Dutch court ruled that Merck infringed Halozyme's patent and ordered Merck to cease manufacturing and selling the subcutaneous formulation of Keytruda in eight European countries. This regulatory setback restricts Merck's ability to commercialize the injectable version of its key cancer therapy in multiple European markets.

Outcome Details

Dutch court ruled that Merck infringed Halozyme's patent and ordered Merck to stop manufacturing and selling subcutaneous Keytruda formulation in eight European countries

Importance:7/10

Sentiment:

-0.90

patent infringementcourt rulingEuroperegulatorysubcutaneous formulationinjunction

Related Companies

$MRK $HALO

Read the original article

Published by Endpoints News on October 7, 2026 6:21 PM

Read Original